BioSpace News Archive

Eisai Co., Ltd. announced that it has submitted an application to the European Medicines Agency for its in-house discovered antiepileptic drug Fycompa seeking approval for use in pediatric patients with epilepsy.

Combination of antibody drug conjugate and checkpoint inhibitor being evaluated for treatment of relapsed or refractory diffuse large B-cell, mantle cell and follicular lymphomas

DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age

Akron Biotechnology, a leading supplier of ancillary materials to the regenerative medicine industry, announces that it has filed a Drug Master File (DMF) Type II for its Interleukin-2 (IL-2) in Electronic Common Technical Document (eCTD) format with the U.S. Food and Drug Administration (FDA).

Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders

February is American Heart Month and Candy Head, the makers of CBD edibles, wants U.S. consumers to investigate the heart-healthy benefits of CBD oil.

Intratumoral delivery of NanoDoce in multiple murine xenograft studies resulted in prolonged, high concentration of drug in tumor tissue, significant tumor regression, and immune cell infiltration

Anixa Biosciences, Inc., a biotechnology company focused on using the body’s immune system to fight cancer, today announced that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center’s 13th Annual Business of Biotech Conference being held on February 22, 2019.

Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, announced that senior management will present at two upcoming healthcare investor conferences.

Clinical study will evaluate safety, tolerability, and immunogenicity in adults